cmd-193
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2004 (NCT00161642)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lewis Y antigenBINDING AGENT
Lewis Y antigen binding agent
- DNADISRUPTING AGENT
DNA disrupting agent
- Lewis Y antigenImmunity, passive
Lewis Y antigen immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- calicheamicin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109672 ↗
- ChEMBLCHEMBL2109504 ↗
Also known as
- cmd-193
- cmd-193
- cmd-193 (111in)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00257881 | Phase 1 | Nov 1, 2005 | Pfizer, Wyeth |
| NCT00161642 | Phase 1 | Nov 1, 2004 | Pfizer, Wyeth |
Showing 2 of 2 trials
Page 1 / 1